Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan- ErbB TKI (Tarlox-TKI)
In Vitro
Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor. MCE has not independently confirmed the accuracy of these methods. They are for reference only.